Japan Experts, Extraordinary Performance, Astris Advisory Japan

Astris Advisory Japan

Japan Experts, Extraordinary Performance

Our Corporate Advisory service is designed to give clients access to a wider range of investors. These include Japan specialists as well as global investors. The goal is to help achieve a fair equity valuation.

Equity Bottom-Up

<ul><li>Cleared two major hurdles, accelerating the path to profitability – Management executed a large-scale restructuring of the U.S. subsidiary RISE Healthcare Group (RHG) and completed the divestiture of the underperforming LeyLine business.</li><li>These actions have materially contributed to narrowing operating losses and advancing the group’s overall turnaround.</li><li>Overseas drove the growth of the Product Rental business – FY results showed strong overseas performance in the Product Rental segment, led by demand from Ukraine and Malaysia.</li></ul>

Cleared two major hurdles, accelerating the path to profitability – Management executed a large-scale restructuring of the U.S. subsidiary RISE Healthcare Group (RHG) and completed the divestiture of the underperforming LeyLine business.These actions have materially contributed to narrowing operating losses and advancing the group’s overall turnaround.Overseas drove the growth of the Product Rental business – FY results showed strong overseas performance in the Product Rental segment, led by demand from Ukraine and Malaysia.

Cyberdyne (7779 JP) - Ongoing Improvement in Reducing Operating Loss

<ul><li>Cost-saving initiatives and divestment – Q1-3 FY3/25 results indicated continued traction for Treatment service in the Americas with 8.6% sales growth, but Product rental sales grew 0.6% YoY (-2.4% YoY under constant currency).</li><li>Operating losses are narrowing YoY, with the positive impact from cost reduction initiatives at Head Office costs as well as R&amp;D.</li><li>We view the announcement to divest the 63.6%-owned subsidiary LeyLine GmbH as a positive surprise, as this will assist in narrowing operating losses further YoY into FY3/26. </li></ul>

Cost-saving initiatives and divestment – Q1-3 FY3/25 results indicated continued traction for Treatment service in the Americas with 8.6% sales growth, but Product rental sales grew 0.6% YoY (-2.4% YoY under constant currency).Operating losses are narrowing YoY, with the positive impact from cost reduction initiatives at Head Office costs as well as R&amp;D.We view the announcement to divest the 63.6%-owned subsidiary LeyLine GmbH as a positive surprise, as this will assist in narrowing operating losses further YoY into FY3/26. 

Cyberdyne (7779 JP) - Renewed Efforts to Drive Profitability

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in margin trading positions of JPX stocks as of Dec 5th. The aggregated net margin trading position is USD19,761m.</li>
<li>We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.</li>
<li>We highlight net margin buy/sell changes in Carta, Toyoda Gosei, Lasertec, Advantest, SoftBank, Mitsui E&amp;S, Mitsubishi UFJ Financial, Disco, Daihen, Nintendo, Carta, Toyoda Gosei, Lasertec, Advantest, Softbank.</li>
</ul>


We analyzed the changes in margin trading positions of JPX stocks as of Dec 5th. The aggregated net margin trading position is USD19,761m.
We tabulate league tables for top/bottom net long/short of margin trading by value, net margin buy as multiple of ADT.
We highlight net margin buy/sell changes in Carta, Toyoda Gosei, Lasertec, Advantest, SoftBank, Mitsui E&amp;S, Mitsubishi UFJ Financial, Disco, Daihen, Nintendo, Carta, Toyoda Gosei, Lasertec, Advantest, Softbank.


JPX Margin Trading Weekly (Dec 5th): Carta, Toyoda Gosei, Lasertec, Advantest, SoftBank, Mitsui E&S

<ul>
<li>The company recorded a significant decline in operating losses in Q1-2 FY3/25, driven by reductions in R&amp;D and Head Office costs.</li>
<li>Sales growth was relatively low at 1.9% YoY, with 18.9% growth YoY in the Americas driven by the Treatment service segment offsetting declines in other regions.</li>
<li>The Medical HAL Lower Limb Type saw 6.1% rental sales growth YoY, with Japan seeing the strongest growth at 12.3% YoY. </li>
</ul>


The company recorded a significant decline in operating losses in Q1-2 FY3/25, driven by reductions in R&amp;D and Head Office costs.
Sales growth was relatively low at 1.9% YoY, with 18.9% growth YoY in the Americas driven by the Treatment service segment offsetting declines in other regions.
The Medical HAL Lower Limb Type saw 6.1% rental sales growth YoY, with Japan seeing the strongest growth at 12.3% YoY. 


Cyberdyne (7779 JP) - Improving Financial Discipline

<ul><li>Q1 FY3/25 results reported 10.5% sales growth YoY and declining operating losses, driven by a combination of treatment service growth in the Americas and cost reduction efforts.</li><li>Operating units of the key HAL Medical Lower Limb Type grew 8.3% YoY to 481 units worldwide, indicating moderate but sustained growth YoY at home and overseas.</li><li>Overseas sales made up 71% of the total, demonstrating the company’s focus on geographic expansion. </li></ul>

Q1 FY3/25 results reported 10.5% sales growth YoY and declining operating losses, driven by a combination of treatment service growth in the Americas and cost reduction efforts.Operating units of the key HAL Medical Lower Limb Type grew 8.3% YoY to 481 units worldwide, indicating moderate but sustained growth YoY at home and overseas.Overseas sales made up 71% of the total, demonstrating the company’s focus on geographic expansion. 

CYBERDYNE (7779 JP) - Overseas Initiatives Driving Sales and Reducing Losses

Japan

CYBERDYNE, INC. researches and develops medical equipment to improve physical  function of patients, support care workers and assist everyday life for disable dpeople.  The main product is cyborg-type robot, HAL (Hybrid Assistive Limb).  The Company also manufactures and sells the medical product as well as providin gservice for the related fields such as rental and trainings.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cyberdyne Inc (7779 JP)

Cyberdyne (7779 JP) - Ongoing Improvement in Reducing Operating Loss

Management executed a large-scale restructuring of the U.S. subsidiary RISE Healthcare Group (RHG) and completed the divestiture of the...

Astris Advisory Japan

Cyberdyne (7779 JP) - Renewed Efforts to Drive Profitability

Q1-3 FY3/25 results indicated continued traction for Treatment service in the Americas with 8.6% sales growth, but Product rental sales grew 0.6%...

Astris Advisory Japan

JPX Margin Trading Weekly (Dec 5th): Carta, Toyoda Gosei, Lasertec, Advantest, SoftBank, Mitsui E&S

We analyzed JPX margin trading positions report for the past week and highlighted Carta (3688 JP), Toyoda Gosei (7282 JP), Lasertec (6920 JP),...

Ke Yan, CFA, FRM

Cyberdyne (7779 JP) - Improving Financial Discipline

The company recorded a significant decline in operating losses in Q1-2 FY3/25, driven by reductions in R&D and Head Office costs.

Astris Advisory Japan

CYBERDYNE (7779 JP) - Overseas Initiatives Driving Sales and Reducing Losses

Q1 FY3/25 results reported 10.5% sales growth YoY and declining operating losses, driven by a combination of treatment service growth in the...

Astris Advisory Japan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)